SION

Sionna Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing small-molecule drugs for cystic fibrosis, a genetic lung disease. Its lead candidates SION-719 and SION-451 target a genetic defect found in about nine in ten people with the condition, aiming to complement the standard therapy Trikafta. Founded in 2019 by two scientists building on decades of CFTR research, the company began life as Sling Therapeutics before renaming itself Sionna in 2021.